These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39389732)

  • 1. The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry.
    Rymer J; Pichan C; Page C; Alhanti B; Bhatt DL; Kochar A; Angiolillo DJ; Diaz M; Wimmer NJ; Waksman R; Ang L; Bach R; Jenkins R; El-Sabae H; Brothers L; Ohman EM; Jones WS; Washam JB; Wang TY; Narcisse D; Basir MB
    J Card Fail; 2024 Oct; 30(10):1233-1240. PubMed ID: 39389732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
    Droppa M; Vaduganathan M; Venkateswaran RV; Singh A; Szumita PM; Roberts RJ; Qamar A; Hack L; Rath D; Gawaz M; Fuernau G; de Waha-Thiele S; Desch S; Schneider S; Ouarrak T; Jaffer FA; Zeymer U; Thiele H; Bhatt DL; Geisler T
    Resuscitation; 2019 Apr; 137():205-212. PubMed ID: 30790690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cangrelor Use Patterns and Transition to Oral P2Y
    Rymer JA; Bhatt DL; Angiolillo DJ; Diaz M; Garratt KN; Waksman R; Edwards L; Tasissa G; Salahuddin K; El-Sabae H; Dell'Anna C; Davidson-Ray L; Washam JB; Ohman EM; Wang TY
    J Am Heart Assoc; 2022 Jun; 11(11):e024513. PubMed ID: 35621210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and safety of cangrelor in patients with suboptimal P2Y
    Selvarajah A; Tavenier AH; Bor WL; Houben V; Rasoul S; Kaplan E; Teeuwen K; Hofma SH; Lipsic E; Amoroso G; van Leeuwen MAH; Berg JMT; van 't Hof AWJ; Hermanides RS
    BMC Cardiovasc Disord; 2021 Jun; 21(1):292. PubMed ID: 34118880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.
    Eisen A; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
    Int J Cardiol; 2018 Jan; 250():49-55. PubMed ID: 29030140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic Stewardship: Evaluation of Platelet Reactivity-Guided Cangrelor Dosing Using the VerifyNow Assay.
    Connery A; Ahuja T; Katz A; Arnouk S; Zhu E; Papadopoulos J; Rao S; Merchan C
    J Cardiovasc Pharmacol; 2024 May; 83(5):482-489. PubMed ID: 38335531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials.
    Vaduganathan M; Harrington RA; Stone GW; Deliargyris EN; Steg PG; Gibson CM; Hamm CW; Price MJ; Menozzi A; Prats J; Elkin S; Mahaffey KW; White HD; Bhatt DL
    JAMA Cardiol; 2017 Feb; 2(2):127-135. PubMed ID: 27902833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.
    Leonardi S; Mahaffey KW; White HD; Gibson CM; Stone GW; Steg GW; Hamm CW; Price MJ; Todd M; Dietrich M; Gallup D; Liu T; Skerjanec S; Harrington RA; Bhatt DL
    Am Heart J; 2012 May; 163(5):768-776.e2. PubMed ID: 22607853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
    Cavender MA; Bhatt DL; Stone GW; White HD; Steg PG; Gibson CM; Hamm CW; Price MJ; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; Harrington RA;
    Circulation; 2016 Sep; 134(10):723-33. PubMed ID: 27482008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periprocedural platelet inhibition with cangrelor in P2Y
    Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
    Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
    Greenbaum AB; Ohman EM; Gibson CM; Borzak S; Stebbins AL; Lu M; Le May MR; Stankowski JE; Emanuelsson H; Weaver WD
    Am Heart J; 2007 Oct; 154(4):702-9. PubMed ID: 17892995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.
    White HD; Chew DP; Dauerman HL; Mahaffey KW; Gibson CM; Stone GW; Gruberg L; Harrington RA; Bhatt DL
    Am Heart J; 2012 Feb; 163(2):182-90.e4. PubMed ID: 22305835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.